Cargando…

Availability of Essential Medicines for Pediatric Oncology in Armenia

BACKGROUND: One of the main contributors in low survival rate in LMIC is the lack of availability of cancer medications for curative, supportive and palliative care. In many developing countries access to cytotoxic medicine is a major challenge. The information about the availability of essential me...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonyan, Tamara, Papyan, Ruzanna, Danielyan, Samvel, Sargsyan, Lilit, Grigoryan, Varduhi, Topchyan, Hakob, Azaryan, Arpina, Tananyan, Armen, Muradyan, Armen, Tamamyan, Gevorg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948909/
https://www.ncbi.nlm.nih.gov/pubmed/31030465
http://dx.doi.org/10.31557/APJCP.2019.20.4.991
_version_ 1783485823285460992
author Simonyan, Tamara
Papyan, Ruzanna
Danielyan, Samvel
Sargsyan, Lilit
Grigoryan, Varduhi
Topchyan, Hakob
Azaryan, Arpina
Tananyan, Armen
Muradyan, Armen
Tamamyan, Gevorg
author_facet Simonyan, Tamara
Papyan, Ruzanna
Danielyan, Samvel
Sargsyan, Lilit
Grigoryan, Varduhi
Topchyan, Hakob
Azaryan, Arpina
Tananyan, Armen
Muradyan, Armen
Tamamyan, Gevorg
author_sort Simonyan, Tamara
collection PubMed
description BACKGROUND: One of the main contributors in low survival rate in LMIC is the lack of availability of cancer medications for curative, supportive and palliative care. In many developing countries access to cytotoxic medicine is a major challenge. The information about the availability of essential medicines for pediatric cancer in the country is not known. The main objective of this study was to determine whether the medications used during the treatment of pediatric cancer are available in Armenia. METHODS: In summer 2016 we conducted a survey in the 3 main pharmacies in Yerevan, which import pediatric cancer medications to Armenia to evaluate whether medications used during cancer treatment are officially registered and available in the country. In addition, the information on official registration was cross-checked with the Ministry of Health of the Republic of Armenia (MOH). Simultaneously, detailed information about the drugs, on type of produced drug company, doses and price intervals was confined from the price lists of the national drug importer companies. RESULTS: The survey included 64 agents in three classes of medication: anti-neoplastics, anti-microbials, and drugs used in supportive care. All of these medications were included in the recent version of the WHO model list of essential medicines. From 30 anti-neoplastic medications on the essential medicines list 22 (73%) were officially registered in Armenia; from 19 anti-microbial drugs all were registered except caspofungin and from 15 supportive care agents 13 (87%) were registered. From registered anti-neoplastic drugs 18% and from antimicrobial drugs 33% were not available in the drug stores. CONCLUSION: This study showed that not all the drugs from the SIOP PODC Essential Medication list for pediatric oncology are officially registered and available in Armenia, and effective drug regulation focusing on the childhood cancer care medicine is needed for improving the situation in the country.
format Online
Article
Text
id pubmed-6948909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-69489092020-02-04 Availability of Essential Medicines for Pediatric Oncology in Armenia Simonyan, Tamara Papyan, Ruzanna Danielyan, Samvel Sargsyan, Lilit Grigoryan, Varduhi Topchyan, Hakob Azaryan, Arpina Tananyan, Armen Muradyan, Armen Tamamyan, Gevorg Asian Pac J Cancer Prev Short Communication BACKGROUND: One of the main contributors in low survival rate in LMIC is the lack of availability of cancer medications for curative, supportive and palliative care. In many developing countries access to cytotoxic medicine is a major challenge. The information about the availability of essential medicines for pediatric cancer in the country is not known. The main objective of this study was to determine whether the medications used during the treatment of pediatric cancer are available in Armenia. METHODS: In summer 2016 we conducted a survey in the 3 main pharmacies in Yerevan, which import pediatric cancer medications to Armenia to evaluate whether medications used during cancer treatment are officially registered and available in the country. In addition, the information on official registration was cross-checked with the Ministry of Health of the Republic of Armenia (MOH). Simultaneously, detailed information about the drugs, on type of produced drug company, doses and price intervals was confined from the price lists of the national drug importer companies. RESULTS: The survey included 64 agents in three classes of medication: anti-neoplastics, anti-microbials, and drugs used in supportive care. All of these medications were included in the recent version of the WHO model list of essential medicines. From 30 anti-neoplastic medications on the essential medicines list 22 (73%) were officially registered in Armenia; from 19 anti-microbial drugs all were registered except caspofungin and from 15 supportive care agents 13 (87%) were registered. From registered anti-neoplastic drugs 18% and from antimicrobial drugs 33% were not available in the drug stores. CONCLUSION: This study showed that not all the drugs from the SIOP PODC Essential Medication list for pediatric oncology are officially registered and available in Armenia, and effective drug regulation focusing on the childhood cancer care medicine is needed for improving the situation in the country. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC6948909/ /pubmed/31030465 http://dx.doi.org/10.31557/APJCP.2019.20.4.991 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Simonyan, Tamara
Papyan, Ruzanna
Danielyan, Samvel
Sargsyan, Lilit
Grigoryan, Varduhi
Topchyan, Hakob
Azaryan, Arpina
Tananyan, Armen
Muradyan, Armen
Tamamyan, Gevorg
Availability of Essential Medicines for Pediatric Oncology in Armenia
title Availability of Essential Medicines for Pediatric Oncology in Armenia
title_full Availability of Essential Medicines for Pediatric Oncology in Armenia
title_fullStr Availability of Essential Medicines for Pediatric Oncology in Armenia
title_full_unstemmed Availability of Essential Medicines for Pediatric Oncology in Armenia
title_short Availability of Essential Medicines for Pediatric Oncology in Armenia
title_sort availability of essential medicines for pediatric oncology in armenia
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948909/
https://www.ncbi.nlm.nih.gov/pubmed/31030465
http://dx.doi.org/10.31557/APJCP.2019.20.4.991
work_keys_str_mv AT simonyantamara availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT papyanruzanna availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT danielyansamvel availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT sargsyanlilit availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT grigoryanvarduhi availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT topchyanhakob availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT azaryanarpina availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT tananyanarmen availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT muradyanarmen availabilityofessentialmedicinesforpediatriconcologyinarmenia
AT tamamyangevorg availabilityofessentialmedicinesforpediatriconcologyinarmenia